Neuronal TGase (TG6) ELISA

ZediXplore TG6-ELISA IgA and IgG (E003 / E004) are not available any more.
The ZediXclusive TG6-ab ELISA kits E103 and E104 are the revised versions of the ZediXplore TG6-ab ELISA kits E003 and E004

Improvements:
  • No need for background subtraction. Therefore, now you can measure up to 40 sera in duplicates with one kit.
  • The calibrators are adapted, so that the more relevant lower titers are covered. Titers (U/mL) obtained by the new E103/E104 kits can be translated to titers of old kit versions E003/E004 and vice versa!
  • Cutoffs are redefined based on a sera collective of 38 blood donors, equally distributed by sex and age, and a collective of 86 patients with various neurological disorders.


Art. No.
Name
Quantity
Price
E103 ZediXclusive TG6-ab ELISA (IgA)
Neuronal transglutaminase (TG6) ELISA IgA
1 Kit/96 wells
550 €
E104 ZediXclusive TG6-ab ELISA (IgG)
Neuronal transglutaminase (TG6) ELISA IgG
1 Kit/96 wells
550 €

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy